Related Experiment Video
Updated: Jul 29, 2026
11:18
Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus
Published on: May 7, 2012
IL-2-activated cord blood mononuclear cells
1Children's Hospital of Orange County Research Institute, Orange, California 91006, USA.
Cytotherapy
|October 21, 2005
Summary
Interleukin-2 (IL-2)-activated cord blood (CB) cells show potent anti-leukemia activity. Eight-day maturation of CB mononuclear cells (MNC) with IL-2 enhances cytotoxic cell populations and cytokine production for potential immunotherapy.
Area of Science:
- Immunology
- Hematology
- Cell Biology
Background:
- Cord blood (CB) research highlights the potential of IL-2-activated CB for eradicating minimal residual disease post-hematopoietic stem cell transplantation.
- This immunotherapy approach requires further pre-clinical investigation using human hematologic malignancy models.
Purpose of the Study:
- To compare the anti-tumor efficacy of IL-2-matured CB mononuclear cells (MNC) against bone marrow (BM) cells.
- To characterize the phenotype and cytokine secretion of IL-2 CB MNC during peak anti-leukemia cytotoxic activity.
Main Methods:
- Phenotypic analysis using flow cytometry.
- Cytokine secretion assessment via ELISA.
- Cytotoxic activity evaluation using cytotoxicity assays.
Main Results:
- IL-2 maturation significantly altered CB MNC phenotype, increasing CD8+, CD16+ CD56+, CD56+, and CD56+ CD8+ populations after 8 days.
- Novel CD8+ CD56+ cells emerged in IL-2-stimulated CB MNC.
- Elevated levels of INF-gamma, TNF-alpha, and GM-SCF were observed, alongside potent lytic activity against tumor targets.
Conclusions:
- Eight-day IL-2 CB MNC cultures peak with increased cytotoxic cells and cytokines, suggesting therapeutic potential.
- Culture duration is critical for optimizing CB IL-2 applications in transplantation to enhance graft-versus-leukemia (GvL) effects.
